diflucortolone has been researched along with Atrophy* in 1 studies
1 other study(ies) available for diflucortolone and Atrophy
| Article | Year |
|---|---|
Local anti-inflammatory activity and systemic side effects of NM-135, a new prodrug glucocorticoid, in an experimental inflammatory rat model.
The local anti-inflammatory activity and systemic side effects of NM-135 (6alpha,9-difluoro-11beta-hydroxy-16alpha-methyl-21[[2 ,3,4,6-tetrakis-O-(4-methylbenzoyl)-beta-D-glucopyranosyl]oxy]-pregna-1, 4-diene-3,20-dione) in croton oil-induced granuloma pouches and ear edema in rats were studied. The local anti-inflammatory activity of NM-135 was stronger than that of betamethasone 17-valerate (BV). As to systemic side effects, BV and diflucortolon valerate (DFV) caused thymolysis at the doses required for the anti-inflammatory activity. In contrast, no clear systemic side effect was observed in rats administered NM-135 at the dose producing the anti-inflammatory activity. These results suggest that NM-135 is a drug exhibiting a high degree of dissociation between the local anti-inflammatory activity and systemic side effects. Topics: Animals; Anti-Inflammatory Agents; Atrophy; Betamethasone Valerate; Croton Oil; Diflucortolone; Disease Models, Animal; Dose-Response Relationship, Drug; Ear; Edema; Exudates and Transudates; Glucocorticoids; Granuloma; Inflammation; Male; Organ Size; Pregnanediones; Prodrugs; Rats; Rats, Sprague-Dawley; Thymus Gland | 1998 |